secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001062822-22-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon Q3 net loss $23.4M; sotagliflozin NDA on track for May 2023; cash $136.2M
--------------------------------------------------------------------------------

- Net loss of $23.4M ($0.13 per share) vs $23.1M ($0.16) in Q3 2021.
- Cash and investments $136.2M at Sep 30, 2022, up from $86.7M at Dec 31, 2021 after $94.3M net proceeds from public offering and private placement.
- NDA for sotagliflozin in heart failure accepted, PDUFA target action date May 2023; mid-cycle review meeting completed.
- Final data from RELIEF-DPN-1 (LX9211) in painful diabetic neuropathy to be presented; enrollment complete in RELIEF-PHN-1 study with top-line data expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282222000041/0001062822-22-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282222000041/lxrx-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001062822-22-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer